YU60986A - Process for obtaining cell lines, which produce surface antigene of hepatitis b - Google Patents

Process for obtaining cell lines, which produce surface antigene of hepatitis b

Info

Publication number
YU60986A
YU60986A YU00609/86A YU60986A YU60986A YU 60986 A YU60986 A YU 60986A YU 00609/86 A YU00609/86 A YU 00609/86A YU 60986 A YU60986 A YU 60986A YU 60986 A YU60986 A YU 60986A
Authority
YU
Yugoslavia
Prior art keywords
antigene
hepatitis
cell lines
produce surface
obtaining cell
Prior art date
Application number
YU00609/86A
Other languages
English (en)
Inventor
J S Salstrom
M L Rohrbaugh
H Thoma
Original Assignee
Endotronics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endotronics Inc filed Critical Endotronics Inc
Publication of YU60986A publication Critical patent/YU60986A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
YU00609/86A 1985-04-15 1986-04-15 Process for obtaining cell lines, which produce surface antigene of hepatitis b YU60986A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP85104521 1985-04-15

Publications (1)

Publication Number Publication Date
YU60986A true YU60986A (en) 1988-10-31

Family

ID=8193449

Family Applications (1)

Application Number Title Priority Date Filing Date
YU00609/86A YU60986A (en) 1985-04-15 1986-04-15 Process for obtaining cell lines, which produce surface antigene of hepatitis b

Country Status (13)

Country Link
EP (2) EP0719863A1 (de)
JP (1) JPS6255088A (de)
CN (1) CN86102640A (de)
AP (1) AP8600035A0 (de)
AT (1) ATE139795T1 (de)
DE (1) DE3650536T2 (de)
ES (1) ES8802440A1 (de)
FI (1) FI861417A0 (de)
IE (1) IE75355B1 (de)
IL (1) IL78472A (de)
SG (1) SG43220A1 (de)
YU (1) YU60986A (de)
ZA (1) ZA862797B (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
JPS62236493A (ja) * 1986-04-08 1987-10-16 Green Cross Corp:The ＨＢウイルスのＰｒｅ　Ｓ領域を含むＨＢｓＡｇの製造方法
IL79740A0 (en) * 1986-08-17 1986-11-30 Yeda Res & Dev Hepatitis vaccine
US5026828A (en) * 1987-02-27 1991-06-25 Merck & Co., Inc. Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast
EP0288198A3 (de) * 1987-04-20 1989-03-29 Takeda Chemical Industries, Ltd. Peptidherstellung
EP0289034B1 (de) * 1987-05-01 1996-11-27 The General Hospital Corporation Transkaryotische Einpflanzung
WO1988010301A1 (en) * 1987-06-22 1988-12-29 Mccormick And Jones Engineering Ltd. Hepatitis b surface antigen vaccine
EP0299242A3 (de) * 1987-06-22 1989-01-25 Medico Labs Ag Heterologe, virale, immunogen wirksame Peptidpartikel
EP1088830A3 (de) * 1987-06-22 2004-04-07 Medeva Holdings B.V. Partikel von Hepatitis B Oberflächenantigen
US5011915A (en) * 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
EP0328123A1 (de) * 1988-02-09 1989-08-16 Eugene Tech International, Inc. Pre-S-reiches Hepatitis-B-Oberflächenantigen
US6306625B1 (en) 1988-12-30 2001-10-23 Smithkline Beecham Biologicals, Sa Method for obtaining expression of mixed polypeptide particles in yeast
ATE112170T1 (de) * 1989-02-07 1994-10-15 Bio Technology General Corp Verfahren zur herstellung und reinigung von hepatitis b-impfstoff.
JP2957195B2 (ja) * 1989-05-17 1999-10-04 株式会社シノテスト Ｂ型肝炎ウイルス抗体検出システム
US5091300A (en) * 1989-08-03 1992-02-25 Merck & Co., Inc. Radio-immuno assay for hepatitis b virus pres2 antibodies
EP0491077A1 (de) * 1990-12-19 1992-06-24 Medeva Holdings B.V. Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten
IL101653A0 (en) * 1991-04-29 1992-12-30 Merck & Co Inc Multiple hepatitis b virus surface proteins which form particles
EP0533263A3 (en) * 1991-09-20 1994-06-08 Merck & Co Inc A multivalent hepatitis b virus vaccine
WO1993012815A1 (fr) * 1991-12-27 1993-07-08 Gensci Limited Procede d'obtention d'un antigene de surface recombine de l'hepatite b, antigene et vaccin a base de celui-ci
FI945483A7 (fi) 1992-05-23 1995-01-20 Smithkline Beecham Biologicals S A Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
CA2139735A1 (en) * 1992-07-08 1994-01-20 Sing-Hiem Yap Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions
CN1063343C (zh) * 1993-04-27 2001-03-21 中国科学院上海生物化学研究所 氨端带前表面抗原决定簇的乙型肝炎表面抗原蛋白
CN1059927C (zh) * 1994-03-10 2000-12-27 中国科学院上海生物化学研究所 羧端带有前表面抗原1抗原决定簇的乙肝表面抗原融合基因及其编码蛋白
US6100043A (en) * 1995-08-04 2000-08-08 The Perkin-Elmer Corporation Recombinant clone selection system
US5843656A (en) * 1995-08-07 1998-12-01 The Perkin-Elmer Corporation Recombinant clone selection system
WO1997006265A2 (en) * 1995-08-07 1997-02-20 The Perkin-Elmer Corporation Recombinant clone selection system
CN1067721C (zh) * 1996-07-04 2001-06-27 中国科学院上海生物化学研究所 含前表面抗原1和2免疫决定簇的乙肝表面抗原
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
US6583279B1 (en) 2001-01-26 2003-06-24 Becton, Dickinson And Company Sequences and methods for detection of hepatitis B virus
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
CN100381171C (zh) * 2004-12-30 2008-04-16 成都生物制品研究所 含前s1、前s2和s抗原决定簇的乙肝表面抗原复合颗粒
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8945582B2 (en) 2006-09-07 2015-02-03 Glaxosmithkline Biologicals S.A. Vaccine
PT2468300T (pt) 2006-09-26 2018-01-30 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2086582T3 (pl) 2006-10-12 2013-04-30 Glaxosmithkline Biologicals Sa Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie
KR101151202B1 (ko) 2006-10-12 2012-06-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 수중유 에멀젼 애주번트를 포함하는 백신
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
BRPI0810778A2 (pt) 2007-05-02 2011-09-13 Glaxosmithkline Biolog Sa kit, vacina combinada, e, métodos de diminuição da interferência de vizinhança de crm sobre um antìgeno sensìvel em um esquema de imunização primária de uma vacina, e de diminuição da interferência de vizinhança sobre um antìgeno sensìvel, e, uso de conjugados de sacarìdeo
AU2009248810B2 (en) 2008-05-23 2013-12-05 The Regents Of The University Of Michigan Nanoemulsion vaccines
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
EP3165540A1 (de) 2010-04-13 2017-05-10 Celldex Therapeutics, Inc. Antikörper zur bindung von humanem cd27 und verwendungen davon
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
KR102136433B1 (ko) 2012-05-16 2020-07-22 이뮨 디자인 코포레이션 Hsv-2 백신
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
EP2986303B1 (de) 2013-04-18 2020-02-26 Immune Design Corp. Gla-monotherapie zur verwendung in der krebsbehandlung
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
US12297266B2 (en) 2016-04-18 2025-05-13 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
US11266602B2 (en) 2016-05-16 2022-03-08 Infectious Disease Research Institute PEGylated liposomes and methods of use
DK3458475T3 (da) 2016-05-16 2022-09-12 Access To Advanced Health Inst Formulering, der indeholder tlr-agonist, og anvendelsesfremgangsmåder
AU2017273650B2 (en) 2016-06-01 2022-08-18 Access To Advanced Health Institute Nanoalum particles containing a sizing agent
JP2020524143A (ja) 2017-06-15 2020-08-13 インフェクシャス ディズィーズ リサーチ インスティチュート ナノ構造脂質担体、安定エマルジョン、およびその使用
CA3078223A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
US11459393B2 (en) 2018-04-17 2022-10-04 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
US20220016168A1 (en) 2018-12-11 2022-01-20 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
EP3976092A1 (de) 2019-05-25 2022-04-06 Infectious Disease Research Institute Zusammensetzung und verfahren zum sprühtrocknen einer adjuvans-impfstoff-emulsion
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
CN111961664A (zh) * 2020-09-08 2020-11-20 武汉中投汉嘉科技有限公司 一种核酸提取液
CA3214853A1 (en) 2021-04-09 2022-10-13 Celidex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
EP4583841A1 (de) 2022-09-09 2025-07-16 Access to Advanced Health Institute Immunogene impfstoffzusammensetzung mit einem saponin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59007A (en) * 1978-12-22 1983-11-30 Biogen Nv Recombinant dna molecules coding for polypeptides displaying hepatitis b virus antigenicity,method of their production and compositions containing the same
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
DE3280392D1 (de) * 1981-11-23 1992-03-26 University Patents Inc Steuerung der dna-sequenzen-transkription.
WO1984002534A1 (en) * 1982-12-23 1984-07-05 Us Commerce Human growth hormone produced by recombinant dna in mouse cells
FR2559159B1 (fr) * 1984-02-02 1986-09-12 Inst Nat Sante Rech Med Vecteurs viraux de clonage et d'expression d'une proteine dans une cellule eucaryote, comportant au moins une partie du genome d'un retro-virus; cellules eucaryotes transfectees; procede utilisant de telles cellules et proteines obtenues

Also Published As

Publication number Publication date
IE75355B1 (en) 1997-08-27
ATE139795T1 (de) 1996-07-15
ES8802440A1 (es) 1988-06-01
EP0719863A1 (de) 1996-07-03
IL78472A (en) 2004-08-31
AP8600035A0 (en) 1987-10-14
DE3650536D1 (de) 1996-08-01
IL78472A0 (en) 1986-08-31
DE3650536T2 (de) 1997-02-27
ES553953A0 (es) 1988-06-01
JPS6255088A (ja) 1987-03-10
EP0198474A1 (de) 1986-10-22
SG43220A1 (en) 1997-10-17
EP0198474B1 (de) 1996-06-26
HK1003794A1 (en) 1998-11-06
IE860965L (en) 1986-10-15
CN86102640A (zh) 1987-04-08
ZA862797B (en) 1988-04-27
FI861417A0 (fi) 1986-04-01

Similar Documents

Publication Publication Date Title
YU60986A (en) Process for obtaining cell lines, which produce surface antigene of hepatitis b
YU15686A (en) Process for producing ceramic complex structure
EP0203581A3 (en) Process for producing graphite
EP0166495A3 (en) Electroforming process
GB8410479D0 (en) Conversion process
EP0178853A3 (en) Conversion process
PL256260A1 (en) Method of obtaining novel alkyl-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinolincarboxylic acids
YU126787A (en) Process for obtaining 9a-aza-9a-homoeritromicyn derivatives
GB8411210D0 (en) Conversion process
PT82917A (en) Process for the preparation of modified enzymes
GB8408804D0 (en) Conversion process
GB8617888D0 (en) Fermentation process
PT80597A (en) Process for preparing di-hydropiridines
PT83293B (en) Process for preparing dihidropyridine-2-hydroxyamines useful asmedicaments
GB8609015D0 (en) Enzymatic process
YU43869B (en) Process for obtaining of 2-oxyndol-1-carboxamide
NZ216233A (en) Process for preparing gas absorbent
HUT46058A (en) Process for producing microcarrier suitable for cell clturing processes
YU116882A (en) Process for obtaining purified hepatitis b surface antigene from human plasma
PL260930A1 (en) Cloned dna obtaining method
GB2179057B (en) Process for the production of biogas
EP0159020A3 (en) Polyphosphazene process
YU6185A (en) Process for obtaining phenoxi-benzaldeniodic derivatives
DE3660597D1 (en) Process for the preparation of 5-fluorotoluene-2,4-disulfochloride
HUT42484A (en) Process for producing alpha1-blocking theophylline derivatives